Decentralized clinical trials in the EU - Strategies and digital solutions for navigating the regulatory landscape


The COVID-19 pandemic accelerated the adoption of DCTs worldwide, but the rate of uptake has not been consistent globally. Some early implementation barriers, including immature digital infrastructures and sponsors’ limited experience with the approach, have been steadily receding as enabling technologies become more prevalent and knowledge of benefits grows. Other obstacles, such as the perception of regulatory barriers, are more challenging to navigate, especially in the EU, where EMA recommendations are not interpreted consistently across countries.

Download this eBook to learn how to navigate the complexity of the regulatory landscape in the EU with the right guidance and resources.